Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $27.22 Average Target Price from Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been given a consensus rating of “Hold” by the nine analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $26.67.

PCRX has been the subject of a number of research analyst reports. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays lifted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. HC Wainwright upped their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 price target on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 price objective on shares of Pacira BioSciences in a research note on Tuesday.

Institutional Trading of Pacira BioSciences

Institutional investors have recently bought and sold shares of the business. Verition Fund Management LLC acquired a new stake in shares of Pacira BioSciences during the 3rd quarter worth about $493,000. Centiva Capital LP acquired a new position in shares of Pacira BioSciences in the 3rd quarter valued at $398,000. State Street Corp boosted its holdings in shares of Pacira BioSciences by 5.8% in the 3rd quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after buying an additional 110,162 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Pacira BioSciences during the 3rd quarter worth $257,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Trading Up 14.7 %

PCRX opened at $26.27 on Friday. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The business has a fifty day simple moving average of $24.84 and a 200-day simple moving average of $20.56. The firm has a market cap of $1.22 billion, a P/E ratio of -12.94 and a beta of 0.71.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.